本帖最后由 老马 于 2012-1-13 21:20 编辑
) A/ B# l4 K5 e4 f: ^ k
; g, ?( H: h. U5 X# j" f5 R5 m爱必妥和阿瓦斯丁的比较
, n$ Q' x9 I4 F o$ k$ p1 x1 D. A
3 r0 A# Y M9 g, ?- Mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ Q) e) H0 N g. ]
) H/ e# v \' Y: T
: M: m# S, r1 t% o, `2 H' z- U- [http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: n4 j. j {: |; k; H7 I* o9 A M( ?
==================================================1 t2 M% j7 B' {7 B5 \& Z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)3 O7 U8 x" F- m1 q4 `& o/ Y
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 [7 X, L8 s' p u: W: R0 r" r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 V& B# s, v; S1 @1 l, R5 w+ x- v4 `
|
11011102001537 )
显身卡
, I3 A9 {4 S) K+ b' k; J+ z _7 E/ {
